SCHEMBL13097151

SCHEMBL13097151

CC(=O)NCCNc1cc(C)nc(N)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.65
ATM Q13315 1/20 0.65
TLR8 Q9NR97 1/20 0.60
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
DNMT1 P26358 1/20 0.45
DNMT3L Q9UJW3 1/20 0.45
DNMT3A Q9Y6K1 1/20 0.45
CYP1A2 P05177 4/20 0.44
CLK4 Q9HAZ1 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP2D6 P10635 2/20 0.43
CYP2C19 P33261 2/20 0.43
HRH4 Q9H3N8 3/20 0.42
MAPT P10636 1/20 0.42
HSP90AB1 P08238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13086696 0.82 GAA (0.48) GAAATMTLR8CYP1A2CLK4
SCHEMBL28151142 0.82 HRH4 (0.51) GAAATMTLR8CYP1A2CLK4
SCHEMBL8585646 0.78 TLR8 (0.81) GAAATMTLR8MEN1KMT2A
SCHEMBL15757068 0.78 NUDT1 (0.62) GAAATMTLR8CYP1A2CLK4
SCHEMBL26345520 0.77 TLR8 (0.78) GAAATMTLR8MEN1KMT2A
SCHEMBL29442374 0.77 TLR8 (0.78) GAAATMTLR8MEN1KMT2A
SCHEMBL5792943 0.76 TLR8 (0.66) GAAATMTLR8MEN1KMT2A
SCHEMBL20434306 0.76 TLR8 (1.00) TLR8MEN1KMT2AALDH1A1MAPK1
SCHEMBL26345522 0.76 TLR8 (0.57) GAAATMTLR8MEN1KMT2A
SCHEMBL6128303 0.74 TLR8 (0.69) GAAATMTLR8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use NOVARTIS AG (CH) 2010-10-14 US disclosed
WO-2009050228-A2 CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES NOVARTIS AG (CH) 2009-04-23 WO disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use CSF1R, CSF3R, MSR1 GAA 1686/4885ATM 1140/4885TLR8 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.